Antibiotic prescribing rates in the US ambulatory care setting for patients diagnosed with influenza, 1997-2001

Gabrielle Ciesla1, Shelah Leader, Jeffrey Stoddard

  • 1MedImmune, Inc., One MedImmune Way, Gaithersburg, MD 20878, USA. cieslag@medimmune.com

Respiratory Medicine
|November 6, 2004
PubMed

Insights

Antibiotic prescribing for influenza is common in US ambulatory care, with 38% of visits resulting in a prescription. This inappropriate use costs $18.5 million annually and may worsen antibiotic resistance.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Pharmacoeconomics

Background:

  • Influenza is a viral illness often treated inappropriately with antibiotics.
  • Antibiotic overuse contributes to antimicrobial resistance and increased healthcare costs.

Purpose of the Study:

  • To determine the rate and cost of antibiotic prescriptions for influenza in US ambulatory care.
  • To analyze trends in antibiotic prescribing for influenza patients.

Main Methods:

  • Utilized federal survey data from 1997-2001 for outpatient trends.
  • Estimated costs using Medicare payments and Red Book average wholesale prices (2003).
  • Focused on all patients and healthy individuals aged 5-49 years.

Main Results:

  • Antibiotic prescribing for influenza occurred in 38% of diagnosed visits.
  • One-third of these prescriptions were for broad-spectrum antibiotics.
  • Annual costs of inappropriate antibiotic use reached $18.5 million.

Conclusions:

  • Widespread antibiotic prescribing for influenza is a significant issue in US ambulatory care.
  • Inappropriate antibiotic use for influenza incurs substantial costs and contributes to resistance.
  • Increased influenza vaccination and viral diagnostic testing could mitigate these trends.

Related Concept Videos

Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...